-
Clin. Pharmacol. Ther. · Sep 2013
ReviewIndustry and regulatory performance in 2012: a year in review.
- H M Dowden, R Jahn, T Catka, A Jonsson, E Michael, Y Miwa, and W Zinkand.
- Strategy Portfolio & Performance, AstraZeneca, Wilmington, Delaware, USA. helen.dowden@astrazeneca.com
- Clin. Pharmacol. Ther. 2013 Sep 1; 94 (3): 359-66.
Abstract2012 was a robust year for new molecular entity (NME) approvals in the major geographic regions. What is behind this apparent improved performance? Has the pharmaceutical industry turned the tide in research and development productivity? In this analysis, we look not only at the number of approvals in 2012 but also at their clinical and market potential. We discuss how changes in the regulatory and reimbursement environment impact current industry performance and how this might evolve.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:
![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.